Recombinant Human INS Protein，His

Insulin (INS) is a crucial hormone involved in glucose metabolism and homeostasis, and its dysfunction is a key factor in diabetes and metabolic disorders. The emergence of recombinant protein technology has revolutionized the production of insulin and insulin analogs, allowing for the synthesis of biologically active proteins in large quantities. Historically, insulin was extracted from animal pancreas, but this method posed ethical and supply chain issues. The development of recombinant DNA technology in the late 20th century enabled the expression of human insulin in microbial systems, such as Escherichia coli and yeast, ensuring a more reliable and safer source. Concurrently, research into insulin's structure and function has led to the design of modified insulin analogs with tailored pharmacokinetic properties, improving glycemic control for diabetes patients. These advancements are significant not only for therapeutic applications but also for understanding insulin's role in various physiological processes. Ongoing research focuses on optimizing production techniques, enhancing the efficacy of insulin therapies, and exploring novel approaches to insulin delivery, such as insulin pods and smart insulin pens. This collective effort aims to address the global diabetes epidemic by providing patients with more effective and accessible treatment options, highlighting the importance of continuous innovation in biotechnology related to INS recombinant protein research.